PL2768493T3 - Fitokannabinoidy do stosowania w leczeniu raka piersi - Google Patents

Fitokannabinoidy do stosowania w leczeniu raka piersi

Info

Publication number
PL2768493T3
PL2768493T3 PL12780523T PL12780523T PL2768493T3 PL 2768493 T3 PL2768493 T3 PL 2768493T3 PL 12780523 T PL12780523 T PL 12780523T PL 12780523 T PL12780523 T PL 12780523T PL 2768493 T3 PL2768493 T3 PL 2768493T3
Authority
PL
Poland
Prior art keywords
phytocannabinoids
treatment
breast cancer
breast
cancer
Prior art date
Application number
PL12780523T
Other languages
English (en)
Inventor
Cristina SANCHEZ
Manuel Guzman
Stephen Wright
Colin Stott
Maria MUNOZ CAFFAREL
Clara ANDRADAS
Eduardo PEREZ GOMEZ
Original Assignee
Gw Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Limited filed Critical Gw Pharma Limited
Publication of PL2768493T3 publication Critical patent/PL2768493T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12780523T 2011-10-18 2012-10-17 Fitokannabinoidy do stosowania w leczeniu raka piersi PL2768493T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1117956.1A GB201117956D0 (en) 2011-10-18 2011-10-18 Phytocannabinoids for use in the treatment of breast cancer
US201161550069P 2011-10-21 2011-10-21
EP12780523.2A EP2768493B1 (en) 2011-10-18 2012-10-17 Phytocannabinoids for use in the treatment of breast cancer
PCT/GB2012/052565 WO2013057487A1 (en) 2011-10-18 2012-10-17 Phytocannabinoids for use in the treatment of breast cancer

Publications (1)

Publication Number Publication Date
PL2768493T3 true PL2768493T3 (pl) 2020-03-31

Family

ID=45219876

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12780523T PL2768493T3 (pl) 2011-10-18 2012-10-17 Fitokannabinoidy do stosowania w leczeniu raka piersi

Country Status (11)

Country Link
US (1) US20140314757A1 (pl)
EP (1) EP2768493B1 (pl)
JP (1) JP6316193B2 (pl)
AR (1) AR088391A1 (pl)
ES (1) ES2751340T3 (pl)
GB (2) GB201117956D0 (pl)
HU (1) HUE047198T2 (pl)
PL (1) PL2768493T3 (pl)
PT (1) PT2768493T (pl)
TW (1) TW201322978A (pl)
WO (1) WO2013057487A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
WO2016084075A1 (en) * 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
WO2017072773A1 (en) * 2015-10-27 2017-05-04 Ilana Nathan Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
CA3006182A1 (en) * 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
JP2019526541A (ja) * 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
NZ743812A (en) * 2016-10-21 2019-12-20 Zelda Therapeutics Operations Pty Ltd Prognostic method and kits useful in said method
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
AU2018100837B4 (en) 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
CA3096287A1 (en) * 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
EP3755318B1 (en) 2018-02-20 2022-08-24 MyMD Pharmaceuticals, Inc. Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders
WO2019222459A1 (en) * 2018-05-18 2019-11-21 Diverse Biotech, Inc. Cannabinoid preparations and therapeutic uses
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
CA3123773A1 (en) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
EP4203925A1 (en) * 2020-08-31 2023-07-05 Nelson Mandela University Cannabinoid combinations and their use in the treatment of cancer
IL307444A (en) * 2021-04-05 2023-12-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of cancer
CN113368085A (zh) * 2021-06-05 2021-09-10 昆明医科大学第一附属医院 大麻二酚在调节肿瘤微生态治疗乳腺癌药物研制中的应用
CN116808176B (zh) * 2023-08-30 2023-12-05 上海彗天锦泽生物医学科技有限公司 一种基于免疫检查点阻断的抗肿瘤药物组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US20110229480A1 (en) * 2008-09-04 2011-09-22 Oxford Biotherapeutics Ltd Pta072 protein
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
EP3470057B1 (en) * 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt

Also Published As

Publication number Publication date
GB2495841A8 (en) 2013-05-29
AR088391A1 (es) 2014-05-28
PT2768493T (pt) 2019-10-30
TW201322978A (zh) 2013-06-16
GB2495841A (en) 2013-04-24
GB2495841B (en) 2016-02-10
EP2768493A1 (en) 2014-08-27
GB201117956D0 (en) 2011-11-30
US20140314757A1 (en) 2014-10-23
JP6316193B2 (ja) 2018-04-25
JP2014530247A (ja) 2014-11-17
EP2768493B1 (en) 2019-07-31
GB201218732D0 (en) 2012-12-05
HUE047198T2 (hu) 2020-04-28
ES2751340T3 (es) 2020-03-31
WO2013057487A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL239007A0 (en) Use of Aribolin to treat breast cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
PH12014500248A1 (en) Treatment of breast cancer
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
IL232530A0 (en) Combined cancer treatment
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
IL228430A0 (en) Cancer treatment
PL2780332T3 (pl) Morfolinylobenzotriazyny do zastosowania w terapii rakowej
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
IL275636A (en) Medical combination for cancer treatment
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer